4 stories mentioning OPTHUpdated 7d ago
Every FINWIRES story that references OPTH, newest first.
Optimi Health (OPTH) said Wednesday it has completed its first export of naturally derived psilocybin to the UK to support a planned phase 2 clinical trial for patients with treatment-resistant depression.The pharmaceutical company said the shipment includes psilocybin biomass and finished 5mg psilocybin capsules.Price: $4.92, Change: $+0.06, Percent Change: +1.19%
Optimi Health (OPTH) said Monday it has secured supplies of naturally derived ibogaine and will begin developing finished drug products this summer at its facility in British Columbia.The company plans to produce 50mg and 100mg ibogaine capsules and establish manufacturing, testing, packaging, and labeling processes.CEO Dane Stevens said interest in ibogaine research is increasing, citing a $50 million Texas program supporting the treatment's development.Optimi said a recent US executive order identified ibogaine among psychedelic therapies targeted for accelerated FDA review and expanded patient access.Ibogaine is being studied for opioid use disorder, PTSD, and traumatic brain injury.Optimi shares rose 20% in Monday trading.Price: $5.55, Change: $+0.91, Percent Change: +19.50%
Optimi Health (OPTI.CN, OPTH), down 12.8% on last look, on Thursday said it raised US$15.0 million in the public share offering connected with its listing on the Nasdaq exchange.Optimi Health, which operates in the field of psychedelic medicine, issued 2.4 million-shares at US$6.25 each. The shares began trading on Nasdaq on May 20, under the symbol "OPTH.""This marks a significant milestone for Optimi," said chief executive Dane Steven. "This financing provides significant strength to our balance sheet and represents the necessary working capital for the growth of our business, with ample runway to scale over the next few years."Optimi Health shares were last seen down $1.05, to $7.15, on the Toronto Stock Exchange.Price: $6.95, Change: $-1.25, Percent Change: -15.24%
Optimi Health (OPTH) shares rose 5.5% to $5.80 as they began trading Wednesday on the Nasdaq Capital Market after the company priced its underwritten public offering of 2.4 million shares at $6.25 each.The stock opened at $5.50 and reached a high of $6.40. The underwriter has an option to buy up to an additional 360,000 shares, the company said Wednesday in a statement.Gross proceeds from the offering, expected to close Thursday, are expected to be $15 million.Optimi plans to use the funds to expand production and distribution in its existing markets and to enter additional markets, including the US.Price: $5.80, Change: $+0.30, Percent Change: +5.45%
